The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.
 
Stephen Chia
Consulting or Advisory Role - Amgen; AstraZeneca; Exact Sciences; Gilead Sciences; Lilly O.; Merck; Novartis; Pfizer; Roche
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Exact Scienes/Genomic Health; Genentech; Gilead Sciences; Merck; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi
 
Patrick Neven
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Radius Health (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Lilly (Inst); Pfizer (Inst); Roche (Inst)
 
Eva M Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Florence Lerebours
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Eisai; Lilly O.; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - Eisai; Mundipharma; Novartis; Pfizer; Roche
 
Manuel Ruiz-Borrego
Consulting or Advisory Role - Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - AstraZeneca; Novartis; Pfizer
 
Pamela Drullinsky
Research Funding - Novartis
 
Aleix Prat
Employment - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Yeon Hee Park
Honoraria - AstraZeneca; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Gencurix (Inst); Genome Insight (Inst); NGeneBio (Inst); Pfizer; Roche (Inst)
 
Dejan Juric
Stock and Other Ownership Interests - PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics
Consulting or Advisory Role - AstraZeneca; Eisai; EMD Serono; Genentech; Ipsen; MapKure; Novartis; PIC Therapeutics; Relay Therapeutics; Syros Pharmaceuticals; Vibliome Therapeutics
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Eisai (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Guardant Health; Inivata; Inivata; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Relay therapeutics; Repare Therapeutics; Roche; Zentalis
Research Funding - AstraZeneca (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Merck Sharpe and Dohme (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche (Inst)
 
Yogesh Chattar
Employment - Novartis
 
Heather Patino
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Murat Akdere
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Hope S. Rugo
Consulting or Advisory Role - Blueprint Medicines; Napo Pharmaceuticals; Puma Biotechnology; Scorpion Therapeutics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Pionyr (Inst); Sermonix Pharmaceuticals (Inst); Taiho Oncology (Inst); Veru (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Merck